The MPP is a public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries, especially for HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for thirteen antiretrovirals, three hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our “Products licensed” page.

MPP in Numbers

9
9 patent holders with MPP signed agreements
19
19 million patient-years through MPP’s generic partners from January 2012 to June 2018
23
23 generic manufacturers and product developers sublicensed from the MPP
18
18 products licensed to the MPP
150+
150+ ongoing pharmaceutical development projects
87% to 91%
87% to 91% of people living with HIV in developing countries covered by the MPP adult licences
92 to 131
92 to 131 countries covered by MPP adults licences
631
631 million dollars saved, from January 2012 to June 2018
  • KPMG calculated savings of USD630.55 million and supply of 18.91 million patient-years of treatments through the MPP’s generic partners from January 2012 to June 2018. Read the report.

 

This website uses cookies to ensure you get the best experience on our website. Learn More